Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)

bottoming out

Over valued.

went up 269% for portofeille.

undervalued bio tech

Despite strong growth in recent months, Gilead Sciences beat them to the punch on hepatitis C, upon which Idenix had hung its hopes. A rebound may take a while.

It is going to get bought out, likely for more than the 2.5 billion or whatever INHX got. I'm thinking 30-35 bucks per share.

Wild card is IDIX over ACHN as only remaining Nuc therapy for hep C, as VRUS and INHS both were acquired at huge premium in this narrowed space competing to develop an all-oral hepatitis C therapy for this epidemic worldwide valued at as much as $3 billion. IDIX has broken out but expect it to run up significantly in the near term based on valuation, pipeline, short covers and new valuation of 18.

There are currently 4000 IDIX shares in my "fund" with break-even of around 5.92 USD.
http://caps.fool.com/Blogs/fund-trades/671856.

2.18

When should I buy this stock? Plz help....

spec

IDIX has a too high valuation compared to its sales potential. It is also loss making.

Biotech = hot.

Oversold (but then again, what isn't?!)

CSOakes @2.51

Oversold with powerful sponsor. Will rebound for at least a 50% gain.

worth a buy for a short term correction below $4 after the crash

The company is sitting on a good amount of cash and has a major backer in the form of Novartis (NVS -- owns over 50% of IDIX's shares). Idenix currently sells a Hepatitis B drug and has a Hep C drug in Phase II trials. They are also working on an HIV drug that is in the extreme early phases of development. The Hep C drug will be used in combination with other drugs, but experienced a setback last year because of GI problems in some patients.

Honestly, I'm not a big biotech/pharma investor, but I like the idea behind this company's products and the potential for both the current Hep B drug and the possible Hep C drug. I generally avoid this realm because I don't have the background to understand the chemistry behind the drugs, but I figured this was an interesting situation to monitor through CAPS. Right now, the market is valuing this company as if it had very little chance at a future. NVS' support and the Hep B drug currently on market seem to mitigate against this pessimism.

What company is this ? Well...it's a small biotec company, Novartis owns more than 10% of it and isnt selling any shares. Novartis bought more than 4 million shares of IDIX at a price over 20 dollars per share. What's the price today ? About 7 dollars. Unfortunally relating to biotec knowledge I'm not Charly Travers and I honestly know nearly nothing about evaluating the inside value biotechnology companies, BUT, I guess the guys from Novartis know a lot and if they bough so many shares at 20 dollars per share I suppose this company is worth 20 dollars per share for somebody, so I might happily throw a couple thousand dollars to buy shares at todays price.

Also, about a year ago SOMMADOSSI JEAN-PIERRE, an Officer, bought 10.000 shares at 9 dollars per share. Ok, 10.000 isnt that many, but the guy might not be swimming in money either.

More info, Market Cap is about 400M and the company is 120M in cash ready to burn.

Price to book value is below 3... at this price I would even buy a big company like Intel, and Enterprise Value/Revenue is a confortable 4, while Microsoft is slighly over 5. If this company was profitable I wouldnt hesitate to call it a value play, this way....I'll just guess that it's a value play :)) The signs are there

Outperform dude! Here be no dragons (hope so).